title: [Update of the topical treatment of psoriasis].
abstract: Topical therapy continues to be one of the pillars of psoriasis management. Topical corticosteroids and vitamin D analogs are the drugs of choice during the induction phase, and vitamin D analogs continue to be drugs of choice for maintenance therapy. Tazarotene and dithranol are suitable options in patients with certain, specific characteristics. The calcineurin inhibitors can be considered to be second-line treatment for psoriasis of the face and flexures. The efficacy and safety of the fixed-dose combination of betamethasone and calcipotriol in the induction phase is greater than that of either drug alone. The combination of corticosteroids with salicylic acid achieves better results than corticosteroids in monotherapy. None of the drugs evaluated stands out over the others in all clinical situations, and their use must therefore be individualized in each patient and adjusted according to the course of the disease.
authors.affiliation: Servicio de Dermatología, Hospital Universitario Germans Trias i Pujol, Badalona, Barcelona, España. jmcarrascosac@hotmail.com
authors.forename: J M
authors.initials: JM
authors.lastname: Carrascosa
authors.forename: F
authors.initials: F
authors.lastname: Vanaclocha
authors.forename: L
authors.initials: L
authors.lastname: Borrego
authors.forename: E
authors.initials: E
authors.lastname: Fernández-López
authors.forename: A
authors.initials: A
authors.lastname: Fuertes
authors.forename: L
authors.initials: L
authors.lastname: Rodríguez-Fernández-Freire
authors.forename: A
authors.initials: A
authors.lastname: Zulaica
authors.forename: A
authors.initials: A
authors.lastname: Tuneu
authors.forename: G
authors.initials: G
authors.lastname: Caballé
authors.forename: E
authors.initials: E
authors.lastname: Colomé
authors.forename: X
authors.initials: X
authors.lastname: Bordas
authors.forename: J M
authors.initials: JM
authors.lastname: Hernanz
authors.forename: C
authors.initials: C
authors.lastname: Brufau
authors.forename: E
authors.initials: E
authors.lastname: Herrera
mesh_terms: D000287:Administration, Topical; D001623:Betamethasone / Q000008:administration & dosage; D002117:Calcitriol / Q000008:administration & dosage / Q000031:analogs & derivatives; D004359:Drug Therapy, Combination; D006801:Humans; D011565:Psoriasis / Q000188:drug therapy*
chemical_list: C055085:calcipotriene; D001623:Betamethasone; D002117:Calcitriol